Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

263 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Development and clinical indications of cetuximab.
Labianca R, La Verde N, Garassino MC. Labianca R, et al. Among authors: garassino mc. Int J Biol Markers. 2007 Jan-Mar;22(1 Suppl 4):S40-6. Int J Biol Markers. 2007. PMID: 17520580 Review.
Reversible palpebral ptosis following oxaliplatin infusion.
La Verde N, Garassino MC, Spinelli G, Scanni A, Sburlati P, Farina G, Labianca R. La Verde N, et al. Among authors: garassino mc. Dig Liver Dis. 2007 Nov;39(11):1041. doi: 10.1016/j.dld.2007.07.162. Epub 2007 Oct 29. Dig Liver Dis. 2007. PMID: 17913604 No abstract available.
Predictive models in palliative care.
Ripamonti CI, Farina G, Garassino MC. Ripamonti CI, et al. Among authors: garassino mc. Cancer. 2009 Jul 1;115(13 Suppl):3128-34. doi: 10.1002/cncr.24351. Cancer. 2009. PMID: 19544541 Free article. Review.
Outcomes of small-cell lung cancer patients treated with second-line chemotherapy: a multi-institutional retrospective analysis.
Garassino MC, Torri V, Michetti G, Lo Dico M, La Verde N, Aglione S, Mancuso A, Gallerani E, Galetta D, Martelli O, Collovà E, Fatigoni S, Ghidini A, Saggia C, Bareggi C, Rossi A, Farina G, Thatcher N, Blackhall F, Lorigan P, Califano R. Garassino MC, et al. Lung Cancer. 2011 Jun;72(3):378-83. doi: 10.1016/j.lungcan.2010.09.009. Epub 2010 Oct 15. Lung Cancer. 2011. PMID: 20950888 Clinical Trial.
Rationale for treatment and study design of tailor: a randomized phase III trial of second-line erlotinib versus docetaxel in the treatment of patients affected by advanced non-small-cell lung cancer with the absence of epidermal growth factor receptor mutations.
Farina G, Longo F, Martelli O, Pavese I, Mancuso A, Moscetti L, Labianca R, Bertolini A, Cortesi E, Farris A, Fagnani D, Locatelli MC, Valmadre G, Ardizzoia A, Tomirotti M, Rulli E, Garassino MC, Scanni A. Farina G, et al. Among authors: garassino mc. Clin Lung Cancer. 2011 Mar;12(2):138-41. doi: 10.1016/j.cllc.2011.03.008. Epub 2011 Apr 11. Clin Lung Cancer. 2011. PMID: 21550561 Clinical Trial.
263 results